Skip to main content

Advertisement

Table 1 Clinical parameters of HFD- and LFD-fed mice treated with vehicle or luseogliflozin

From: Luseogliflozin attenuates neointimal hyperplasia after wire injury in high-fat diet-fed mice via inhibition of perivascular adipose tissue remodeling

  HFD LFD
Vehicle Luseogliflozin Vehicle Luseogliflozin
Number 12 8 5 5
Food intake (g/day) 3.2 ± 0.3a 4.1 ± 0.5bc 4.8 ± 0.9 2.9 ± 0.2a
Water intake (g/day) 3.0 ± 0.3ab 6.0 ± 0.7c 7.6 ± 2.5 6.6 ± 0.4
Initial body weight (g) 40.5 ± 2.7ab 43.6 ± 5.1ab 28.7 ± 1.3 27.6 ± 2.3
Final body weight (g) 44.0 ± 2.5ab 45.5 ± 5.7ab 30.2 ± 2.2 28.2 ± 2.0
Body weight increase (g) 3.4 ± 0.9ab 1.8 ± 1.2c 1.5 ± 0.9 0.6 ± 1.0
Liver index (mg/g) 40.3 ± 7.8 38.1 ± 8.0 43.4 ± 4.1 44.1 ± 2.8
Fat index (mg/g) 59.8 ± 5.4ab 57.6 ± 9.8ab 7.5 ± 1.1 9.8 ± 2.1
Pulse (beat/min) 716 ± 70 733 ± 23 746 ± 32 709 ± 45
Systolic blood pressure (mmHg) 125 ± 6 132 ± 8ab 111 ± 14 112 ± 13
HbA1c (%) 5.1 ± 0.2b 5.0 ± 0.3 5.1 ± 0.1 4.8 ± 0.1
Plasma glucose (mg/dl) 186 ± 33ab 168 ± 20a 87 ± 12 127 ± 19
Plasma insulin (ng/ml) 0.33 ± 0.20ab 0.25 ± 0.17 0.04 ± 0.01 0.07 ± 0.05
Plasma glucagon (pmol/l) 7.5 ± 5.8 7.3 ± 5.0 4.2 ± 2.4 7.5 ± 4.7
Plasma total cholesterol (mg/dl) 177 ± 10ab 199 ± 21abc 78 ± 8 93 ± 7
Plasma HDL-cholesterol (mg/dl) 107 ± 6ab 111 ± 4ab 62 ± 8 75 ± 6a
Plasma triglycerides (mg/dl) 65 ± 10a 72 ± 9a 49 ± 3 68 ± 8a
Plasma free fatty acid (mEq/l) 0.50 ± 0.05 0.51 ± 0.03 0.48 ± 0.12 0.53 ± 0.06
  1. Values are shown as mean ± standard deviation
  2. HbA1c glycated hemoglobin HDL high-density lipoprotein
  3. One-way ANOVA followed by Tukey’s test: ap < 0.05 vs. LFD-Vehicle
  4. bp < 0.05 vs. LFD-Luseogliflozin
  5. cp < 0.05 vs. HFD-Vehicle